Tag Archives: Obamacare

Feds Take a Pass on Co-Pay Offsets Under Obamacare

Feds Take a Pass on Co-Pay Offsets Under Obamacare The implosion of the Affordable Care Act’s vaunted healthcare.gov benefit enrollment process has obscured a far more critical issue for big Pharma:  how much leeway do companies have in promoting durable brand affiliations among the potentially millions of new patients with subsidized access to new  medicines? […]
Posted in healthcare, Regulatory | Also tagged , , , , | Leave a comment

CEOs Sound Out on Health Reform: Stop Swinging from the Fence

At last week’s  4th annual Prix Galien Forum hosted by the Alexandria Center in New York, industry leaders gathered to discuss trends and developments that shape the intersection between science and policy.  The centerpiece of the day was a panel on  US health reform – focused on rollout of the  Affordable Care Act — featuring […]
Posted in Events, leadership, People, R&D, Regulatory | Also tagged , , , , , , , , , , , | Leave a comment

The Rx Industry, PBMs, and Obamacare

By Tom Norton A significant, though as yet not fully understood player in the launch of Obamacare is the pharmacy benefit manager (PBM) industry.  This uncertainty, due in part to the current Obamacare IT chaos, has more than a few Rx leaders worrying about how the PBMs tied to insurers in the program will end […]
Posted in Guest Blog, healthcare, Op-Ed | Also tagged , , , , , , , | 2 Comments

Forbes Health Summit: Industry Leaders Ponder the New World of Consumer-Driven Care

In health care, it is the lowly consumer who is now calling the shots, driving product and process innovation in areas ranging from electronic medical records [EMR] to retail health clinics. This was the main theme among discussants at the Forbes magazine Healthcare Summit held here in New York on October 10.  The central question:  […]
Posted in leadership, Meetings, patient education, R&D, Strategy | Also tagged , , , , , , , , , , | Leave a comment

National Chains Carefully Circle Obamacare

by Tom Norton While US Pharma anxiously watches the initial roll out of Obamacare, there are those entities closely associated with the innovator Rx business that have a very different view on what Obamacare means to their concerns.  These firms are carefully circling the new law, thoughtfully observing its implementation, and, generally, viewing its startup […]
Posted in Guest Blog, healthcare, leadership, Legal, Market Access, Regulatory | Also tagged , , , , , , , , , | Leave a comment
  • Categories

  • Meta